Market news

BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.

Baxter International has underperformed the Nasdaq over the past year, and analysts are cautious about the stock’s prospects.

CVS, Steris and Baxter are oversold healthcare stocks with RSI readings near or below 30, potentially offering undervalued buying opportunities.

Sophie Baxter has set up a social group for "emos, goths and moshers" who never left the noughties.

Injecting the potentially contaminated drugs could cause blood clots, organ damage and other health issues, according to the FDA.

FOR IMMEDIATE RELEASE – AUG. 25, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of 70% Dextrose Injection due to the potential presence of particulate matter identified as stainless steel particles in the solution.

John Rogers is expected to take the Deerfield, Illinois-based medical device company’s CFO seat on Oct. 1.

DEERFIELD, Ill., August 19, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026.

Divers in Florida are seeking sunken slave ships for connections to history.

DEERFIELD, Ill., August 04, 2026--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has commenced cash tender offers (each, an "Offer" and collectively, the "Offers") for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million.

Baxter International is back in focus after the fair value estimate in one widely used model moved from US$21.54 to US$27.29, a change of about 27% that feeds directly into updated price target discussions. Analysts are linking this shift to fresh views on earnings execution, segment performance and medium term growth visibility after the latest Q2 results and guidance. As you read on, you will see how to track these changing views and what to watch as the Baxter International story develops...

Baxter International Inc. recently reported past Q2 2026 results, with sales rising to US$2,960 million and quarterly net income increasing to US$126 million compared with the prior year. Alongside this, Baxter raised its 2026 sales growth and adjusted earnings guidance while maintaining a quarterly dividend, signaling management’s confidence in its operating direction. Next, we’ll examine how Baxter’s upgraded 2026 guidance, particularly its higher sales outlook, shapes the company’s...

The company's second-quarter performance was impressive.

Baxter (BAX) delivered earnings and revenue surprises of +55.56% and +5.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Shares of healthcare company Baxter International (NYSE:BAX) jumped 8.7% in the afternoon session after the company reported second-quarter results that beat analyst expectations on the top and bottom lines and raised its full-year financial forecast.

Healthcare company Baxter International (NYSE:BAX) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.3% year on year to $2.96 billion. Its non-GAAP profit of $0.56 per share was 52.5% above analysts’ consensus estimates.

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Healthcare company Baxter International (NYSE:BAX) will be reporting results this Thursday before market open. Here’s what you need to know.

Shares of healthcare company Baxter International (NYSE:BAX) jumped 3.6% in the afternoon session after TD Cowen raised its price target on the stock to $24 from $20. The firm maintained its hold rating on the shares, which suggests the analyst recommends neither buying nor selling the stock at its current price. However, the increased price target indicates a more positive valuation outlook for the company than before. The move from the investment firm comes as Baxter holds an average rating of

BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The leader of South Kesteven District Council says the changes "beggar belief".

AbbVie and Baxter both flashed the same bullish technical signal this month, but one golden cross signals genuine momentum while the other masks a fundamentally broken business. Knowing which is which could protect your retirement income from a costly mistake.

DEERFIELD, Ill., July 09, 2026--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/167756971 to pre-register for the call and receive the call information.

Baxter International will release its second-quarter earnings soon, and analysts anticipate a double-digit profit dip.

Index additions put fresh attention on Baxter International Baxter International (BAX) has been added to both the Russell 2500 Index and the Russell 2500 Value Benchmark, a shift that can influence index tracking flows and bring the stock onto more investor radars. See our latest analysis for Baxter International. Recent price action reflects that attention. Baxter International’s share price is US$22.58, with a 30-day share price return of 16.51% and a 90-day share price return of 35.86%...

Baxter International Inc. was recently added to both the Russell 2500 Index and the Russell 2500 Value Benchmark, expanding its presence among US equity indices and index-tracking portfolios. This dual index inclusion, combined with broadly positive sentiment and supportive near- and mid-term outlooks, has drawn fresh attention from institutional investors and quantitative trading strategies focused on the stock. We’ll now examine how Baxter’s new Russell 2500 inclusion, alongside...